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Abstract
Background: New York City (NYC) remains an epicenter of the HIV epidemic in the United States. Given the variety of
evidence-based HIV prevention strategies available and the significant resources required to implement each of them,
comparative studies are needed to identify how to maximize the number of HIV cases prevented most economically.
Methods: A new model of HIV disease transmission was developed integrating information from a previously validated
micro-simulation HIV disease progression model. Specification and parameterization of the model and its inputs, including
the intervention portfolio, intervention effects and costs were conducted through a collaborative process between the
academic modeling team and the NYC Department of Health and Mental Hygiene. The model projects the impact of
different prevention strategies, or portfolios of prevention strategies, on the HIV epidemic in NYC.
Results: Ten unique interventions were able to provide a prevention benefit at an annual program cost of less than
$360,000, the threshold for consideration as a cost-saving intervention (because of offsets by future HIV treatment costs
averted). An optimized portfolio of these specific interventions could result in up to a 34% reduction in new HIV infections
over the next 20 years. The cost-per-infection averted of the portfolio was estimated to be $106,378; the total cost was in
excess of $2 billion (over the 20 year period, or approximately $100 million per year, on average). The cost-savings of
prevented infections was estimated at more than $5 billion (or approximately $250 million per year, on average).
Conclusions: Optimal implementation of a portfolio of evidence-based interventions can have a substantial, favorable
impact on the ongoing HIV epidemic in NYC and provide future cost-saving despite significant initial costs.
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Introduction
New York City (NYC) remains an epicenter of HIV in the U.S.
More than 110,000 New Yorkers are living with HIV, and almost
3,500 new cases of HIV were diagnosed in 2010 [1]. NYC’s AIDS
case rate is almost 3 times the U.S. average, and HIV is the third
leading cause of death for NYC residents aged 35 to 54 [2]. While
no single prevention strategy has materialized to control the HIV
epidemic, a number of behavioral and biomedical approaches have
been developed that reduce the risk of HIV infection [3]. In fact,
some investigators have theorized that the HIV epidemic can even
be extinguished in certain settings with systematic prioritization and
implementation of a package of aggressive interventions (e.g.,
universal annual testing, prompt linkage to care, and immediate
antiretroviral therapy [ART] initiation) [4]. However, these
interventions require substantial resources, and it remains unclear
how to best allocate HIV prevention resources to maximize the
number of new HIV cases prevented. Furthermore, detection and
care patterns in the US differ considerably from the optimistic
assumptions of recent models [4].
While the National HIV/AIDS Strategy (preventing new
infections, increasing access to care, and reducing HIV-related
health disparities) [5] and the new focus of CDC’s ’’High-Impact
Prevention’’ (HIP) (intensifying the use of appropriately combined
evidence-based prevention methods in the most highly affected
geographic areas) [6] may provide new momentum to HIV
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prevention efforts in the United States, additional tools to
prioritize and focus currently available prevention intervention
strategies are clearly needed.
Previous modeling work comparing variegated HIV prevention
interventions and strategies has been relatively scarce to date and
has been associated with several limitations. For example, while a
cost-effectiveness analysis of HIV prevention interventions was
particularly helpful because it enabled interventions to be rank-
ordered by absolute benefit and cost-per-infection averted, [7] it
did not permit decision makers to individualize results based on
the strength and quality of the evidence (e.g., controlled trial based
data vs. observational data). Additionally, a similar model has
evaluated prevention strategies from a nationwide perspective
which may not account for jurisdiction-level differences in
transmission dynamics, cost, and political feasibility of various
interventions, all of which can contribute to local micro-epidemics
and require setting-specific solutions [8].
We created a jurisdiction-specific operations research model of
HIV prevention in NYC to account for complexities and local
dynamics inherent in HIV transmission and treatment. This model
deployed the set of evidence-based HIV prevention interventions
outlined in the 2010 Center for Disease Control’s Enhanced
Comprehensive HIV Prevention Planning (ECHPP) grant, Phase I
(see Table 1) [9]. The aims of this project were to inform HIV
prevention planning in the jurisdiction by comparing cost-per-
infection averted between the various ECHPP strategies and by
identifying the optimal package of prevention services in NYC.
Methods
Overview
An operations research model was constructed to inform HIV
prevention decisions in NYC. This model incorporates informa-
tion from an individual-based, stochastic simulation of HIV
progression into a deterministic epidemic model of HIV transmis-
sion. The simulation estimates the HIV epidemic over varying
time horizons up to 20 years. Different combinations of preven-
tion strategies (‘‘packages’’) were tested. Costs were estimated on
Table 1. HIV prevention interventions and associated costs considered in transmission simulation.
Abbreviation ECHPP Intervention description
Cost range
considered1
Level of
Evidence2
Testing – clinical Enhanced routine opt-out screening for clinical settings $37–147 B
Testing – non-clinical HIV testing in non-clinical settings to identify undiagnosed HIV infection $109–162 B
Condom distribution Condom distribution prioritized to specific populations $0.05–$1.00 A
Post-exposure prophylaxis (PEP)3 Provision of Post-Exposure Prophylaxis to populations $1312–$3938 C
Linkage to care Implement linkage to HIV care, treatment, and prevention services
for those testing HIV positive and not currently in care
$1078–$1424 B
Care coordination Implement interventions or strategies
promoting adherence to antiretroviral medication
and retention in care for HIV-positive persons
$3000–$9000 B
STD Implement STD screening according to
current guidelines for specific populations
$178–230 D
Partner services Implement ongoing partner services for HIV-positive
persons (i.e., provision of partner services both at
the time of diagnosis and as needed thereafter)
$748–2244 B
Risk reduction Behavioral risk screening followed by risk reduction
interventions for HIV-positive persons (including those for
HIV-discordant couples) at risk of transmitting HIV
$1000–2813 D
Linkage to support services Implement linkage to other medical and
social services for HIV-positive persons
$398–1194 D
Social marketing HIV and sexual health communication or social marketing
campaigns targeted to relevant audiences
$4–13 D
Community-level evidence based
interventions
Evidence based community interventions that reduce HIV risk $0.37–$1.10 D
Prioritized use of surveillance data Targeted use of HIV and STD surveillance data to prioritize
risk reduction counseling and partner services for persons
with previously diagnosed HIV infection with a new STD
$52–157 D
Social services For HIV-negative persons at highest risk , linkages
to social support services impacting HIV incidence
$88–263 D
Screening, brief intervention, and
referral to treatment for unhealthy
alcohol users (SBIRT)
Brief alcohol screening, interventions and referral to treatment $55–156 C
Cofactors Brief screening and treatment for comorbid STDs,
substance use and mental health.
$55–156 C
1For all interventions shown (with the exception of linkage to care), cost ranges considered reflect the cost in 2010 USD for each prioritized individual based on actual or
estimated programmatic costs incurred by NYC DOHMH. For linkage to care, cost estimate comes from Gardner LI, et al. 2005 [25].
2Level of evidence assignment reflects weakest evidence for a specific intervention’s effects on pathway(s).
3Includes cost of medications required.
doi:10.1371/journal.pone.0073269.t001
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an incremental basis in 2010 US dollars. Benefits were measured
as number and percentage of infections averted (as compared to
the base case). Cost-per-infection averted ratios were determined
for each package, uncertainty bounds around each estimate were
created by evaluating each intervention using the lower and upper
bounds of efficacy considered (Table 2). Key model parameters
were varied in sensitivity analysis. For the purposes of this analysis,
a threshold of $360,000 per infection averted was selected as cost-
saving, since the downstream medical costs averted from
preventing a new infection would offset the programmatic costs
of preventing that new infection [10].
We sought to identify strategies delivering the greatest health
benefit for a particular a budget scenario, also known as efficient
frontiers [11]. Strategies outside this frontier are unable to deliver
the greatest benefit regardless of budget, and therefore are not
preferred choices regardless of available resources. We identified
efficient frontiers by calculating the incremental cost-effectiveness
ratio (ICER) of combinations of HIV prevention strategies. ICERs
measure the additive benefit of each strategy compared with its
next best alternative, and interpret this benefit together with its
additive cost.
We identified all intervention strategies that the model
estimated would be cost-saving and subsequently ran twenty year
simulations of each combination of these interventions (n = 16 cost
saving interventions, 10 of which were unique; 65,535 possible
combinations of any number of n). The intervention portfolios that
delivered the greatest benefit for any particular budget scenario
(that is, the efficient frontier) were identified using well-established
methods [12]. The ‘‘optimal’’ package of interventions we
assumed to be represented by the farthest point lying on the
frontier as this combination prevented the largest number of
infections and yet remained cost-effective to implement.
HIV transmission
A deterministic compartmental model of HIV transmission was
developed, specified by sets of equations. The model was
implemented in the C++ programming language. Full details of
the conceptualization and parameterization of the model can be
found in File S1. The model includes both sexual transmission and
transmission through needle-sharing during injection drug use.
HIV transmission was modeled using a binomial process and
assumed proportionate mixing in the population. The probability
of transmission between partners was adjusted to account for
infected partner’s gender, disease state and treatment status.
Differences in risk associated with sexual positioning and
positioning preferences between MSM were not considered.
HIV progression and treatment
Disease progression was modeled by incorporating equilibrium
mortality and transition rates between CD4 and HIV-1 viral load
(VL) categories as a function of antiretroviral treatment and
adherence from a previously described and validated HIV
stochastic progression simulation model. Accordingly, the output
distributions of the progression model (stochastic) were collapsed
into point estimates as a byproduct of enabling the transmission
and progression models to exchange information. The progression
model explicitly represents the main cause of ART failure, non-
adherence leading to the accumulation of genotypic resistance,
and has been well-validated in multiple populations [13,14].
The HIV positive population in the transmission simulation at
baseline was divided into compartments based on CD4 and VL
strata. Five CD4 strata were represented (,50, 51–200, 201–350,
351–500, .500 cells/mm3) and five VL logarithmic strata were
represented (,2.5, 2.5–3.5, 3.5–4.5, 4.5–5.5, .5.5 log copies/ml).
The spectrum of infection and care was modeled as a stepwise
progression from HIV acquisition/primary infection to chronic
infection, HIV detection thorough testing, linkage to care,
Table 2. Intervention-pathway effect parameter inputs into ECHPP HIV epidemic computer simulation.
InterventionRpathway effects Effect Size1
Sensitivity
Analysis limits Reference
Condom distribution/use 12.3% increase (RR ,1.12) 3.3–21.5% Charania et al 2010 [26]
Enhanced clinic based HIV testing 32.7% increase (RR,1.33) 29.6–39.5% Anaya et al 2008 [27], Calderon et al 2011 [28],
Mullins et al 2010 [29]
Community based HIV testing 10.2% increase (RR,1.10) 8.0–18.9% Rhodes et al 2011 [30], Wilton et al 2009 [31]
PEP utilization 42.0% increase (RR ,1.42) 25.0–70.0% Barash et al 2010 [32]
Linkage to care 30.0% increase (RR,1.30) 9.0–37.5% Gardner et al 2005 [25,33]
Care coordination/Case management 20.0% increase (RR,1.20) 7.5–32.0% Hart et al 2010 [34], Simoni et al 2006 [35]
STD care and treatment 28.0% decrease (RR,0.72) 8.0–51.0% Grosskurth H et al 1995 [36]
SBIRT component effect size2 15.0% decrease (RR,0.85) 5.0–25.0% Bertholet N et al 2005 [37]
Partner services intervention3 2.8% increase 2.0–5.0% Hogben et al 2007 [38], unpublished data from
NYC DOH
IDU risk reduction 67.4% decrease (RR ,0.33) 15.2–88.5% Latkin et al 2003 [39], Robles et al 2004 [40]
Risky sexual practices 25.0% decrease (RR,0.75) 1.0–50.0% Vissers et al, 2011 [41]
RR: risk ratio; PEP: Post-exposure prophylaxis; STD: sexually transmitted disease; SBIRT: screening, brief intervention and referral for treatment for unhealthy alcohol use;
IDU: injection drug use.
1Values of intervention effect sizes represent relative risk benefits on pathway applied to prioritized population(s) except where noted. For instance, if an intervention
included a condom distribution/use component, this would result in a 12.3% increase in the probability of consistent condom usage amongst a specified risk group.
2The SBIRT intervention acts to reduce the proportion of the population classified as unhealthy alcohol users. The effect size represents the relative decrease in this
proportion.
3The partner services intervention acts to identify previously unknown persons with HIV. The effect size value represents the proportion of undetected HIV positive
individuals who move from the ‘‘chronic HIV’’ state to the ‘‘in care’’ state if the intervention is activated.
doi:10.1371/journal.pone.0073269.t002
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initiation of treatment with antiretroviral therapy, and adherence
to therapy.
Representation of HIV prevention interventions
The transmission simulation includes the capacity to represent
the implementation of one or more HIV prevention interventions.
Each intervention was assumed to impact a specifiable group or
population by activating one or more pathways to reduce HIV
transmission (see Table 2 and File S1 for further details). Here,
‘pathway’ refers to a fundamental mechanism through which
transmission is impacted (e.g. such as reducing the likelihood of
unprotected anal intercourse), or by reducing the probability of
transmission given that a high-risk act occurs (e.g. such as the
likelihood of transmission during unprotected anal intercourse
when an HIV positive person is virally suppressed) (Figure 1). Note
that while some interventions are restricted to a particular
prioritized group by their design (such as medical case manage-
ment, or care coordination for HIV-positive individuals), other
interventions may be applied to multiple alternative groups (for
example, a condom distribution intervention can be alternatively
directed at HIV-persons with high-risk behaviors, all HIV-infected
persons, HIV-negative persons with high-risk behaviors, or all
persons). Prioritized groups for a given intervention are repre-
sented in the model by specifying particular compartments of
specific populations or risk groups (Table 1 and File S1).
The effect of each intervention on each pathway is summarized
using the metrics of effect size (Table 2), statistical certitude (95%
confidence interval or plausible range) (Table 2), and strength of
evidence (‘‘grades’’ A, B, C, or D), based on the investigator’s
published adaptation of the evidence rating scale used by the
United States Preventive Services Task Force (Table 3) [15]. Any
model input with an evidence source that could not be confirmed
was conservatively assigned a default grade of ‘‘D’’ (Table 1). An
intervention was assigned a single level of evidence equivalent to
the ‘‘weakest link’’ in any evidence associated with it (e.g. efficacy
of effect on a specific HIV transmission pathway, uptake of
intervention) for the purposes of examining effects of filtering by
uncertainty.
Under model scenarios where multiple interventions were
incorporated and were hypothesized to affect a similar HIV
transmission pathway we assumed conservatively that the effect of
the strongest intervention would predominate and the weaker
intervention(s) would have no additional effect on that specified
pathway (though their effects on any additional unique pathways
would be maintained). For instance, if intervention A (acting only
through increased condom utilization) prevented 1,000 new
infections and intervention B (acting only through increased
condom utilization) prevented 2,000 new infections the combina-
tion package of A+B would only result in 2,000 new infections
being averted. If, however, A or B had additional effects beyond
condom utilization the combination of A+B could prevent more
than 2,000 infections over the model run.
Parameter inputs
The population of NYC in 2009 (ages 0–75) based on NYC
HIV surveillance data [16] was divided into population compart-
ments based on gender, sexual risk behavior, sexual identity
(straight, gay, bisexual), infection status, treatment status, and
Figure 1. Schematic of constructs in transmission simulation and pathways which impact HIV transmission.
doi:10.1371/journal.pone.0073269.g001
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injection drug use (IDU) (Table 4). Sexual risk was divided into
three categories (abstinent, monogamous, multiple concurrent
partnerships). Proportions of the population within each sexual
risk category remain constant over time. Serial partnerships (i.e.
multiple partners in serial fashion over time) were considered as
monogamous. Abstinent persons were estimated to represent 21%
of the population [17]. The mean CD4 for the initial HIV positive
population was 350 cells/mm3, and the mean VL was 4.5 log [18].
Persons were defined as ‘‘high-risk’’ (for the purposes of
intervention prioritization) if they had multiple sexual partnerships
(whether MSM or heterosexual men or women) and/ or were
injection drug users (IDUs). Other critical inputs were ascertained
from literature estimates, or through discussion and consensus
amongst the study team (Table 5). For the purposes of model
specification, odds ratios derived from the peer-reviewed literature
were converted to appropriate risk ratios using previously defined
techniques when necessary [19].
Costs were considered from the perspective of the NYC
Department of Health and Mental Hygiene (NYC DOHMH)
and the City of New York. Costs were derived per intervention
from estimates of programmatic expenditures within the
DOHMH and did not include costs incurred by other (non-
DOHMH funded) agencies. Programmatic costs typically include
pro-rated staff time, fixed costs and additional materials required
to provide the given intervention (e.g., educational tools or
supplies, including the cost of purchasing condoms). Where
feasible, fee-for-service rates that incorporate these costs for each
unit of service were applied. Plausible cost ranges for many
interventions were provided; if no range was given, sensitivity
analyses employed 650% of the estimated cost as the bounds.
Annual costs for an intervention were calculated using a ‘‘pre-
purchasing’’ perspective – total cost for an intervention equals per
unit cost specific to the intervention (cost input from Table 1) times
the total number of persons estimated to be in the priority
population.
Calibration, validation, and design features
The base case time horizon is 20 years. We performed
sensitivity analyses with alternative time horizons of potential
interest for policy decisions (5 years and 10 years). We did not
discount costs or benefits. We pre-specified three validation
criteria to test whether the model’s predictions were compatible
with observed results: HIV prevalence, HIV incidence, and HIV-
related mortality. We compared data from the most recent year
available (2009), as well as time trends over the longest period of
time (2003 to 2009) during which NYC data were available for all
three criteria. In addition, we tested whether the distribution of
new infections across three risk categories (i.e. MSM, heterosexuals
and IDU) predicted by the simulation resembles observed results.
Results
Model calibration and validation
Comparing simulation estimations with epidemiological data
from NYC, the simulation demonstrated reasonable goodness of fit
with pre-specified validation criteria of HIV incidence and HIV
prevalence, over the timeframe for which NYC data was available
(2003 through 2009) (Figure 2a–b). In addition, the proportions of
new infections among different risk categories (MSM, heterosex-
uals and IDUs) and the overall prevalence predicted by the
simulation during the first year closely resembled the relevant 2009
NYC data (Figure 2).
Results with baseline investment in HIV prevention
programs
Under the base case assumptions, without incremental invest-
ment in HIV prevention programs or strategies, the model
predicted 58,632 new cases of HIV infection over a 20 year time
period, with an average incidence of 2,932 new infections per year.
Over the 20 year simulation, 16,159 persons were predicted to
Table 3. Evidence filters for model inputs.
Level of
Evidence Filter Grading Criteria (Assessment of internal validity based on criteria outlined in Braithwaite RS, et al. 2007[15])
A Systematic review including meta-analysis or individual randomized controlled trial (internal validity: high)
B High quality observational studies (cohort, case-control; internal validity: high) or lower quality individual randomized
controlled trial (internal validity: fair or poor)
C Lower quality observational studies (internal validity: fair or poor)
D Expert opinion
doi:10.1371/journal.pone.0073269.t003
Table 4. Initial New York City-based HIV inputs into ECHPP HIV epidemic computer simulation, 20091.
Subgroup Male HIV+ (known) Female HIV + (known) Total HIV+ (known)
Adults (13–65) 76,770 31,596 108,366
Transmission Risk 2
Heterosexual 5,637 (7%) 15,081 (48%) 20,718 (19%)
MSM 35,882 (47%) – 35,882 (33%)
IDU 15,051 (20%) 6,151 (19%) 21,202 (20%)
1NYC DOHMH, Bureau of HIV/AIDS Prevention and Control, surveillance data, 2009 [42].
2Proportion of HIV-positive adults with a reported transmission risk. Proportions do not equal 100% because of persons with unknown transmission risk.
doi:10.1371/journal.pone.0073269.t004
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Table 5. Generalized inputs into ECHPP HIV epidemic computer simulation.
Parameter or input Value
Sensitivity
analysis limits Reference
Sexual risk characteristics
Proportion of population who are abstinent 21.0% 17.0–32.0% Adimora, et al 2007[17]
Probability of monogamous relationship (if sexually active)
Men who have sex with women (MSW) 78.2% … CHS [43]
Men who have sex with men (MSM) 55.8% … [43]
Women who have sex with men (WSM) 91.1% … [43]
Women who have sex with women (WSW) 48.9% … [43]
Probability of multiple partnerships (if sexually active)
MSW 21.8% 16.1– 23.6% [43]
MSM 44.2% 25.6–63.6% [43]
WSM 8.9% 6.9–10.4% [43]
WSW 51.1% … [43]
Proportion of men who are MSM 5.6% 2–10% [43]
Proportion of men who are MSW 94.4% … [43]
Proportion of women who are WSW 2.4% … [43]
Proportion of women who are WSM 97.6% … [43]
Injection Drug Use Characteristics
Proportion of population that injects drugs 1.43% 1.33–1.91% Brady JE, et al 2008 [44]
Proportion of injection drug users (IDUs) who have unsafe injection
practices
32% 15%–50% NHBS NYC Data 2009 [45]
Proportion of IDUs who are male 70% … NHBS NYC Data 2009 [45]
Sexual and IDU transmission
Transmission risk per sex act
Male-to-male 0.00167* … Jin F [46]; Baggaley[47]
Female-to-male 0.00042 … Boily[48]
Male-to-female 0.00081 … Boily[48]
Transmission risk per unsafe needle sharing act 0.003 … Tokars JL, et al 1993 [49]
Relative risk of transmission if viral load
0–2.5 log copies/ml 0.16 … Attia S, et al 2009 [50]
2.5–3.5 log copies/ml 1.87 … [50]
3.5–4.5 log copies/ml 6.54 … [50]
4.5–5.5 log copies/ml 8.85 … [50]
.5.5 log copies/ml 9.03 … [50]
Sex acts (per partnership) per year 89 69–112 Mosher WD, et al 2005 [51]
Shared injections per year 70 25–100 Assumption
HIV risk behaviors and biological/behavioral modifiers of
transmission
Prevalence of untreated sexually transmitted infection 6.9% 0.1–10% Epiquery—STD registry [52];
Benedetti J, et al 1994 [53]
Prevalence of unhealthy alcohol use 5% 2–10% Wunsch-Hitzig R, et al 2003 [54]
Prevalence of consistent condom usage 35% 20–50% CHS [43]
HIV disease related
Probability of annual HIV test 31% 20%–50% CHS [43]
Probability of linkage to care 75% … Unpublished NYC DOMH data
Probability of initiating ART if in care 87% 65–95% Unpublished NYC DOMH data
Demographics
Age-related mortality rate 0.0068 (6.8/1000 pop) … NYC vital statistics, 2009 [16]
Fertility rate 0.0156 (15.6/ 1000
pop/year)
… NYC Vital statistics 2009 [16]
ART: antiretroviral therapy; * represents an average of different risks per act based on sexual positioning.
doi:10.1371/journal.pone.0073269.t005
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have died of AIDS-related conditions, with an average 808 deaths
per year.
Results with increases in investment in HIV prevention
programs
Simulation of the implementation of each of the considered
HIV prevention interventions resulted in fewer overall number of
infections and HIV/AIDS-related deaths than the base case
scenario; however, there was notable heterogeneity in the effect
and the cost-per-infection averted of each strategy (Table 6). Some
of the interventions with the potential to avert the greatest number
of new infections (e.g., post-exposure prophylaxis) had a very high
cost (.$9 million per-infection averted).
Analysis limited to cost-saving interventions
A group of ten unique interventions had the potential to be cost-
saving: condom distribution; social marketing; community-based
prevention; prioritized use of surveillance data (i.e., targeted use of
HIV and STD surveillance data to prioritize risk reduction
counseling and partner services for persons with previously
Figure 2. Validation of the HIV epidemic model. a. Comparing model prevalence results with reported data for New York City for 2003–2009. b.
Comparing model incidence results with reported data from New York City 2003–2009. c. Comparison of observed versus simulated results, based on
most recent year for which DOHMH results are available.
doi:10.1371/journal.pone.0073269.g002
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Table 6. Selected single policy options, and their impact on HIV infections averted and the cost per infection averted.
Intervention Target Group
Total cost (x
$1million), 20
years
# new infections,
20 years
# infections
averted,
20 years
Cost per
Infection
Averted
Favorable
Value
(Yes/No)
Base case (No additional
interventions)
N/A N/A 58,632 N/A N/A
Condom distribution HIV-infected, high-risk $4.5 57,118 (58,227–
55,977)
1,514 (405–2,655) $2,969 ($1,690–
11,100)
Yes
Social marketing HIV-infected $18.6 53,280 (48,287–
57,895)
5,352 (737–10,345) $3,474 ($1,770–
25,500)
Yes
Condom
distribution
HIV-infected $13.5 56,321 (54,581–
58,014)
2,312 (619–4,052) $5,854 ($3,326–
21,966)
Yes
Community
intervention
All $82.9 47,071 (37,701–
57,085)
11,562 (1,548–20,931) $7,173 ($3,962–
53,570)
Yes
Prioritized use of
surveillance data
HIV-infected $16.7 58,029 (57,480–
58,560)
603 (73–1,152) $27,663 ($14,405–
230,854)
Yes
Cofactors HIV-infected, high-risk. $65.5 56,540 (55,744–
57,344)
2,092 (1,288–2,888) $31,304 ($25,948–
58,741)
Yes
SBIRT HIV-infected, hazardous
alcohol users
$11.6 58,316 (58,250–
58,381)
317 (251–382) $36,772 ($35,032–
53,330)
Yes
Social marketing Providers $715.6 49,832 (42,565–
57,467)
8,801 (1,165–16,607) $81,315 ($44,544–
614,177)
Yes
Social marketing All $954.2 47,071 (37,701–
57,085)
11,562 (1,548–20,931) $82,532 ($45,595–
616,407)
Yes
Linkage to care HIV-infected $59.6 57,852 (56,860–
58,426)
780 (206–1,772) $380,906 ($161,007–
1,564,241)
Yes
Social marketing HIV-uninfected, high-risk $935.1 49,997 (43,377–
57,203)
8,635 (1,429–15,255) $108,291 ($61,314–
654,404)
Yes
Condom distribution HIV-uninfected, high-risk $358.5 55,847 (53,771–
57,884)
2,785 (748–4,861) $128,715 ($73,747–
479,120)
Yes
Linkage to support HIV-infected $1,681.9 45,100 (37,198–
54,584)
13,532 (4,048–21,434 $124,291 ($76,929–
425,376)
Yes
Condom distribution All $590.3 55,479 (53,132–
57,785)
3,153 (847–5,501) $187,212 ($107,311–
696,563)
Yes
Partner services HIV-infected and partners $74.0 58,259 (58,232–
58,288)
373 (344–400) $198,253 ($184,854–
215,195)
Yes
STD screening HIV-infected, high-risk $332.1 57,653 (57,380–
57,966)
980 (666–1,253) $339,026 ($264,888–
499,101)
Yes
STD screening HIV-infected $501.1 57,584 (57,291–
57,919)
1,048 (713–1,341) $477,984 ($373,509–
703,563)
No
Risk reduction HIV-infected $4,107.7 53,280 (48,287–
57,895)
5,352 (737–10,345) $767,431 ($391,903–
5,637,789)
No
Social services HIV-uninfected, high-risk $3,986.6 54,822 (51,710–
58,082)
3,810 (550–6,922) $1,046,387 $568,274–
7,340,070)
No
Care coordination HIV-infected, on ART $12,597.5 47,755 (41,841–
54,717)
10,877 (3,915–16,791) $1,158,199 $740,254–
3,268,504)
No
Testing – clinical HIV uninfected $8,124.0 54,024 (52,036–
55,831)
4,608 (2,801–6,597) $1,763,061 ($1,231,602–
2,899,854)
No
Testing – non-clinical HIV-uninfected $13,110.1 54,417 (51,444–
57,566)
4,215 (1,066–7,188) $3,110,381 ($1,823,909–
12,298,571)
No
Cofactors HIV-uninfected, high-risk $2,298.8 57,999 (57,592–
58,407)
633 (225–1,040) $3,631,257 ($2,537,148–
11,767,147)
No
SBIRT HIV-uninfected, high-risk $540.9 58,493 (58,442–
58,544)
139 (88–190) $3,895,458 ($3,276,457–
7,079,913)
No
PEP HR(-) HIV-uninfected, high-risk $176,466.0 40,632 (41,427–
52,469)
18,000 (6,164–17,205) $9,803,449 ($10,256,032–
28,602,672)
No
STD screening HR(-) HIV-uninfected, high-risk $15,437.6 57,279 (56,903–
57,711)
1,354 (921–1,730) $11,404,509 ($8,924,995–
16,758,381)
No
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diagnosed HIV infection with a new STD); cofactor risk reduction;
screening, brief intervention and referral for treatment for
unhealthy alcohol use (SBIRT); linkage to care; linkage to support
services for HIV-positive persons; partner services (defined here as
just partner notification and testing); and STD screening. These
ten unique interventions could avert each new HIV infection at a
lower cost than the estimated downstream cost of that infection
[10].
When the simulation evaluated all possible combinations of
these ten interventions (16 non-unique interventions) that are
potentially cost-saving and sought to identify the package of
interventions that would avert the most HIV infections for
particular budget scenarios, seven of these interventions were
included in the different packages located on the efficient frontier,
including condom interventions (prioritized for high-risk HIV-
infected persons), social marketing for HIV-infected persons,
community interventions, interventions to address cofactors for
HIV-infected persons, linkage to support for HIV-infected
persons, and partner services (Figure 3). For an additional budget
of ,$1 million USD annually, a social marketing campaign
focused on persons living with HIV could avert an additional
5,352 (9%) new HIV infections over the next twenty years
(Package 2; Figure 3).
The package of potentially cost-saving interventions predicted
by the model to prevent the most infections was implementation of
evidence-based community-level interventions, STD screening for
high-risk HIV infected persons, partner services, and a linkage to
support interventions (Package 7; Figure 4). Such a package would
result in 20,211 (34%) of new HIV infections averted. The cost per
infection averted for this package is predicted to be $106,378;
however, the total cost savings would be more than $5 billion (or
approximately $250 million per year, on average) because the
$2 billion of program costs over the 20 year time horizon would be
offset by the predicted downstream savings from infections averted
totaling more than $7 billion. This package would result in a
corresponding early increase in prevalence followed by a later
decline, reflecting the package’s impact on the kinetics of detection
and entry into care (Figure 4).
Analyses considering all interventions regardless of cost
The package of interventions predicted by the model to prevent
the greatest number of infections (without regard for cost, in order
of strongest effect) included expanded provision of post-exposure
prophylaxis for HIV uninfected persons, linkage to support, social
marketing for HIV-infected persons, evidence-based community
level interventions, and enhanced HIV testing in clinical settings.
An estimated 33,004 (56%) of infections would be averted
implementing this package of interventions at an estimated cost-
per infection averted of nearly $9 million (see File S2).
Implementation of a package of interventions representing a
‘‘test and treat’’ only strategy (i.e., enhanced HIV testing in clinical
settings, linkage to care intervention and care coordination
intervention) without some of the other interventions listed above
included in the portfolio, assuming uptake of testing, linkage and
treatment at levels predicted in the literature, resulted in 14,048
(25%) infections averted during the twenty year simulation.
However, near perfect efficacy of ‘‘test and treat’’ (i.e., universal
annual screening, immediate linkage to care, universal ART, and
perfect adherence to ART) predicted that .80% of new HIV
infections would be averted and the cost-per-infection averted
would be ,$360,000. In addition, reduction by a factor of ten in
the cost of the ‘‘test and treat’’ package rendered the intervention
cost-saving even under the base case efficacy assumptions.
Sensitivity analysis
Several of the interventions had .10% absolute change in their
projected effectiveness in one-way sensitivity analysis (see File S2).
Varying all parameters (listed in Tables 1–2 and 4–5) across the
plausible ranges for each and evaluating the effects of all
interventions under these conditions demonstrated that the
prevention interventions considered to be of favorable value were
robust. No intervention with a cost-per-infection averted greater
than the $360,000 threshold under base case assumptions crossed
this threshold under any other conditions. However, several of the
interventions, including condom distribution to high risk, HIV-
negative persons; linkage to support; condom distribution to the
whole population; partner services; and STD screening for high-
risk, HIV-infected persons, that were considered cost-saving under
base case assumptions had cost-per-infection ratios which
increased above the threshold considered as cost-saving under
other, specific conditions (see File S2).
Under conditions where ART initiation was not restricted by
CD4 count (as has been recommended by the DHHS [20]) there
were no differences in the list of interventions that were considered
to be cost-saving or in the relative rankings of interventions by
cost-per-infections averted (data not shown). Similarly, when we
varied the time horizon of the analysis, the group of interventions
considered cost-saving did not change (see File S2).
Effects of optimization by level of evidence
The efficient frontiers of combined HIV prevention interven-
tions were highly dependent on quality of evidence criteria. If
Table 6. Cont.
Intervention Target Group
Total cost (x
$1million), 20
years
# new infections,
20 years
# infections
averted,
20 years
Cost per
Infection
Averted
Favorable
Value
(Yes/No)
PEP HIV-uninfected $284,790.0 39,042 (26,554–
46,910)
19,590 (11,722–32,076) $14,537,519 ($8,884,247–
24,285,093)
No
STD screening – all All $25,423.1 57,191 (56,791–
57,651)
1,441 (981–1,841) $17,640,475 ($13,805,927–
25,920,175)
No
Results are shown for infections averted over a time horizon of 20 years. Costs reflect additional increases in expenditures. An intervention is considered to be of
favorable value if cost-per-infection averted ,$360,000). Values in parenthesis represent upper and lower bounds of estimates related to assumptions regarding
intervention efficacy (lower, upper).
SBIRT: screening, brief intervention and referral for treatment for unhealthy alcohol use; STD: sexually transmitted disease; PEP: Post-exposure prophylaxis.
HR(2): high risk, HIV-uninfected.
doi:10.1371/journal.pone.0073269.t006
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analysis was limited to only those packages supported by the
strongest evidence (Level A), only condom distribution interven-
tions would be included in the intervention portfolio. However, as
evidence limitations were relaxed to include all interventions
supported by at least some observational data, more interventions
were included in the intervention portfolio, and more infections
could be averted, albeit at a higher cost (see File S2).
Discussion
We have developed an innovative, jurisdiction-specific simula-
tion that can identify the most cost-effective portfolio of
interventions to maximize HIV infections averted in a major
urban area of the United States for a defined budget. Great
variation was found in the cost per infection averted by the HIV
prevention strategies considered, ranging more than 1,000-fold.
Ten of these interventions prevented new HIV infections at
favorable value, with costs-per-infection averted falling below the
expected downstream costs of the HIV infections (had they
occurred). Our results suggest that the highest value interventions
focus on individuals already HIV-infected, rather than the much
larger number of individuals who are not known to be HIV-
infected, reinforcing conclusions from Lasry et al [21]. While not
suggesting that prevention resources should be targeted exclusively
to HIV-infected persons, our results do indicate that altering the
balance of services in favor of HIV-infected persons, particularly
those at high risk of onward transmission, may avert a high
proportion of new infections at relatively low cost.
Figure 3. Efficient frontier for HIV prevention interventions found to have ‘‘favorable value’’ during a 20 year simulation of HIV
epidemic in NYC. a. Graphical representation of frontier. Diamonds represent packages of intervention(s) on the frontier. b. Interventions and the
pathways they activate contained within each efficient frontier package. X, pathway activated within package.
doi:10.1371/journal.pone.0073269.g003
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Figure 4. Epidemic curves for 20 year simulation. Black line- Base case scenario; Grey line- optimized package (Package 7 from Figure 3b)
implemented. a. New HIV diagnoses over 20 years. b. HIV prevalence over 20 years. c. HIV incidence over 20 years.
doi:10.1371/journal.pone.0073269.g004
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While the results varied somewhat in sensitivity analyses that
considered statistical uncertainty, they did not vary sufficiently to
alter likely decisions about intervention prioritization. A similar
group of interventions fell below the cost-of-infection threshold,
regardless of the optimism of assumptions or the time horizon
used. Results do appear to be very sensitive to analyses that
considered uncertainty of level of evidence. When we required that
only level A and B evidence interventions were considered, the
optimized package of interventions could only avert 6% of
infections as compared to 23% when relaxing the evidence criteria
to include all intervention strategies supported by some observa-
tional data (levels A–C).
While others have reported results of a model using an
extremely optimistic ‘‘test and treat’’ strategy in the South African
context, suggesting potential reductions in HIV infections of up to
95% [4], our model found much more conservative results, albeit
with much more conservative assumptions. With base-case
assumptions, an ‘‘optimized’’ package of non-ART dependent
interventions would reduce new infections by 20–30%, whereas
under assumed thresholds a ‘‘test and treat’’ strategy alone would
reduce new infections to a lesser degree (,25% reduction), but at a
greater cost. However, if we are able to approach the theoretical
limits of ‘‘test and treat’’ efficacy (universal annual screening,
immediate linkage, universal ART and perfect adherence) near
elimination of ongoing HIV transmission could be realized. Our
results are consistent with model based cost-effectiveness estimates
of similar intervention strategies published previously [7,8,21,22].
For the many evidence-based interventions that can prevent
large numbers of infections but only at very high costs per infection
averted (e.g., PEP, adherence interventions) scale up across a large
segment of the population who may be at low risk of HIV
acquisition or transmission may be cost prohibitive. For those
individuals with both high infectivity and ongoing behavioral risk
(for example, a probability of infecting at least one other person of
greater than 10% per year), up to $18,000 could be spent per year
(over 20 years) on a highly tailored package of HIV-reduction
interventions for that person while still spending less than $360,000
to avert each infection. Our results suggest the potential benefit of
developing even more sophisticated operations research to
prioritize the allocation of resources to these individuals more
effectively, despite the inherent challenges of doing so.
It is important to note that NYC’s high rates of testing (31% of
adult NYC residents reported HIV testing in past 12 months in
2009) and linkage to care (75% of persons diagnosed were linked
to care in 3 months in 2009 using prevailing definitions) may have
had an important impact on our findings because we analyzed
marginal rather than absolute resource allocation questions (i.e.,
additional benefit from increased funding rather than expected
benefit from existing funding). Interventions to improve linkage to
care had comparatively small effects, and correspondingly
unfavorable cost-effectiveness, because the vast majority of newly
infected NYC were already linked during the period of study.
Similarly, interventions to improve testing rates had comparatively
small effects, and correspondingly unfavorable cost-effectiveness,
because a substantial proportion of New Yorkers were already
tested for HIV annually during the period of study.
Limitations
Like any computer simulation, not all inputs are known with
certainty, and results are partially dependent on the assumptions
embedded in the model. Costs in our model were not addressed
from the comprehensive societal perspective, but were rather
assessed based primarily on the costs to local public health
authorities in NYC. They may not be inclusive or reflective of all
costs incurred by society or specific payers. Specifically, the cost of
antiretroviral therapy for treatment is not included here, largely
because this particular model sought to specifically address the list
of initial CDC ECHPP interventions on which this model was
originally based. A related limitation is that some of the more
innovative and recently approved biomedical interventions, such
as rapid HIV self-testing and pre-exposure prophylaxis (neither of
which were part of ECHPP nor FDA-approved at the time of
model development/validation) were not modeled here. Modal-
ities still under investigation, such as microbicides or HIV
vaccines, were also not included. Further, interventions considered
in the model are not always discrete (i.e., interventions may impact
more than one of the components/pathways), and some may be
defined more narrowly in the model than they are implemented in
reality (e.g., partner services can link persons to care and services
and distribute condoms in addition to partner notification and
testing). In general, interactions between different interventions
are also not taken into account here, either wasteful or synergistic.
Per-person costs in our model were derived from programmatic
estimates from the DOHMH and were applied in a ‘‘pre-
purchased’’ approach (i.e., extrapolating the cost to assume that
every intervention is purchased every year in a sufficient quantity
to reach every person in the target population). This neither
accounts for the potential economies of scale that may be
operational nor the actual utilization of an intervention (as
represented by its effect size in our model). Therefore, potential
bias towards overestimation of costs of interventions may occur,
leading to a more conservative estimate of portfolios of interven-
tions that may be ‘‘cost-saving.’’ This bias may explain, in part,
why expanded HIV testing in our model appears to be less cost-
effective than it was found to be in other published mathematical
models [23,24]. In addition, our model does not explicitly consider
costs of the antiretroviral medications or the routine care needed
by a person living with HIV/AIDS, although these costs informed
the estimation of the $360,000 threshold.
Assumptions we made may have also contributed to the model’s
limitations. We made assumptions about the mechanisms of action
of the HIV prevention interventions and the lack of interactions
between interventions when more than one was implemented as a
part of a specific package. Our mapping process (assessing which
pathways were influenced by which interventions) was reviewed
and agreed upon by members of both the academic modeling
team and the DOHMH, and many of these assumptions were
based on expert opinion where sufficient data was unavailable or
inadequate. There are little to no reliable data to inform how
different interventions would impact on each other if implemented
in tandem. We chose a conservative approach by hypothesizing
that specific interventions act through mutually exclusive mech-
anisms and that a pathway for a specific person/population could
only be ‘‘activated’’ once no matter how many interventions
affected it.
Conclusions
This computer simulation, constructed using operations re-
search methods, may be useful to inform program and policy
decisions for HIV prevention and care in NYC and other major
urban areas. Based on the needs and settings of particular
decision-makers, this model can represent the interplay between
different combinations of interventions and can generate highly
jurisdiction-specific results. After validation of this model using
inputs from the NYC epidemic and incorporating the interven-
tions prioritized in CDC’s ECHHP project, these results suggest
that many infections can be prevented at acceptable cost by
systematically prioritizing and implementing known interventions.
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Preliminary results from this modeling effort were used, in part, to
help inform the development of a new solicitation for HIV
prevention services in New York City as well as pilot clinic-based
activities that prioritize secondary HIV prevention interventions
among persons living with HIV in NYC.
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